Yuhan Corp (Yuhan) discovers, develops, manufactures and markets pharmaceutical products. It offers APIs and intermediates for antibiotic, antiviral, antifungal, anti-thrombotic, anti-inflammatory, anti-diabetic, and anti-hyperlipidemics. The company offers finished goods for the treatment of hypertension, coronary artery disease, hyperlipidemia, cerebral thrombosis and other diseases. Yuhan provides custom synthesis services for other pharmaceutical and biopharmaceutical companies. It offers active pharmaceutical ingredients (API) and finished products in domestic as well as international market. Yuhan operates R&D and manufacturing facilities in Seoul. The company offers its products and services through its sales and distribution branches. Yuhan is headquartered in Seoul, South Korea.

Headquarters South Korea

Address 74, Noryangjin-Ro, Dongjak-Gu, Seoul, 06927


Telephone 82 2 8280181

No of Employees 1,594

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 000100 (KRX)

Revenue (2021) $1.5B 4.2% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -46.8% (2021 vs 2020)

Market Cap* $3.3B

Net Profit Margin (2021) XXX -48.9% (2021 vs 2020)

* As of and is in US$

Access premium data and analytics for Yuhan Corp

270+

Marketed Drugs

Understand Yuhan Corp’s commercialized product portfolio to stay one step ahead of the market.

150+

Clinical Trials

Determine Yuhan Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

130+

Pipeline Drugs

Identify which of Yuhan Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Yuhan Corp’s relevant decision makers and contact details.

50+

Catalyst Calendar

Proactively evaluate Yuhan Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Yuhan Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services Brands
APIs & Intermediates: Custom Synthesis Service Viread
Levofloxacin Hemihydrate Supply Chain Management Trajenta
Piperacillin Monohydrate Twynsta
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Acquisitions/Mergers/Takeovers In September, the company acquired Atogen, a microbiome research and development company.
2022 Contracts/Agreements In September, the company entered into a partnership with Progen to develop new drugs using Progen's multi-target antibody platform technology.
2022 Financing Agreements In January, the company along with Premier Partners, K2 Investment Partners, Shinvestor & Partners, BNH Investment, E & Investment, and Hanyang Securities and others invested US$20.5 million in ImmuneOncia Therapeutics through pre-IPO funds.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Yuhan Corp GC Corp Daewoong Pharmaceutical Co Ltd Huons Global Co Ltd Yuyu Pharma Inc
Headquarters South Korea South Korea South Korea South Korea South Korea
City Seoul Yongin Hwaseong Seongnam Jecheon
No. of Employees 1,594 170 1,256 541 243
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Jung Hee Lee Chairman Executive Board 2015 68
Wook Je Cho President; Chief Executive Officer Executive Board 2021 65
Byung Man Lee Head - Over the Counter Drugs Business Department; Director; Head - Business Management Division; Vice President Executive Board 2018 61
Jae Kyo Kim Director; Head- Global Strategy Department; Vice President Executive Board 2018 52
Chong Hyun Park Head - Pharmaceutical Business Division; Director; Vice President Executive Board 2017 61
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?